Article
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.
PloS one - 1 Jan 2014
Maasoumy Benjamin, Hunyady Bela, Calvaruso Vincenza, Makara Mihály, Vermehren Johannes, Haragh Attila, Susser Simone, Bremer Birgit, Cloherty Gavin, Manns Michael P, Craxì Antonio, Wedemeyer Heiner, Sarrazin Christoph
Abstract excerpt
INTRODUCTION: On-treatment HCV RNA measurements are crucial for the prediction of a sustained virological response (SVR) and to determine treatment futility during protease inhibitor-based triple therapies. In patients with advanced liver disease an accurate risk/benefit calculation based on reliable HCV RNA results can reduce the number of adverse events. However, the different available HCV RNA assays vary in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.